223 related articles for article (PubMed ID: 23899187)
41. Quantitative assessment of AKAP12 promoter methylation in colorectal cancer using methylation-sensitive high resolution melting: Correlation with Duke's stage.
Liu W; Guan M; Su B; Ye C; Li J; Zhang X; Liu C; Li M; Lin Y; Lu Y
Cancer Biol Ther; 2010 Jun; 9(11):862-71. PubMed ID: 20364105
[TBL] [Abstract][Full Text] [Related]
42. CpG island methylation affects accessibility of the proximal BRCA1 promoter to transcription factors.
Xu J; Huo D; Chen Y; Nwachukwu C; Collins C; Rowell J; Slamon DJ; Olopade OI
Breast Cancer Res Treat; 2010 Apr; 120(3):593-601. PubMed ID: 19466541
[TBL] [Abstract][Full Text] [Related]
43. Altered methylation of glucosylceramide synthase promoter regulates its expression and associates with acquired multidrug resistance in invasive ductal breast cancer.
Liu J; Zhang X; Liu A; Zhang D; Su Y; Liu Y; You D; Yuan L; Kong X; Wang X; Sun P
Oncotarget; 2016 Jun; 7(24):36755-36766. PubMed ID: 27191984
[TBL] [Abstract][Full Text] [Related]
44. Microarray analysis of gene expression in metastatic gastric cancer cells after incubation with the methylation inhibitor 5-aza-2'-deoxycytidine.
Chen J; Röcken C; Klein-Hitpass L; Götze T; Leodolter A; Malfertheiner P; Ebert MP
Clin Exp Metastasis; 2004; 21(5):389-97. PubMed ID: 15672863
[TBL] [Abstract][Full Text] [Related]
45. Correlation between the single-site CpG methylation and expression silencing of the XAF1 gene in human gastric and colon cancers.
Zou B; Chim CS; Zeng H; Leung SY; Yang Y; Tu SP; Lin MC; Wang J; He H; Jiang SH; Sun YW; Yu LF; Yuen ST; Kung HF; Wong BC
Gastroenterology; 2006 Dec; 131(6):1835-43. PubMed ID: 17087954
[TBL] [Abstract][Full Text] [Related]
46. Aberrant hypermethylation of the HOXD10 gene in papillary thyroid cancer with BRAFV600E mutation.
Cao YM; Gu J; Zhang YS; Wei WJ; Qu N; Wen D; Liao T; Shi RL; Zhang L; Ji QH; Wang Y; Sun GH; Zhao YX; Wang YJ; Yu J; Zhu YX
Oncol Rep; 2018 Jan; 39(1):338-348. PubMed ID: 29115628
[TBL] [Abstract][Full Text] [Related]
47. Methylation-mediated regulation of the glutathione S-transferase P1 gene in human breast cancer cells.
Jhaveri MS; Morrow CS
Gene; 1998 Mar; 210(1):1-7. PubMed ID: 9524203
[TBL] [Abstract][Full Text] [Related]
48. A genome-wide screen for promoter methylation in lung cancer identifies novel methylation markers for multiple malignancies.
Shames DS; Girard L; Gao B; Sato M; Lewis CM; Shivapurkar N; Jiang A; Perou CM; Kim YH; Pollack JR; Fong KM; Lam CL; Wong M; Shyr Y; Nanda R; Olopade OI; Gerald W; Euhus DM; Shay JW; Gazdar AF; Minna JD
PLoS Med; 2006 Dec; 3(12):e486. PubMed ID: 17194187
[TBL] [Abstract][Full Text] [Related]
49. Radioresistance in a human laryngeal squamous cell carcinoma cell line is associated with DNA methylation changes and topoisomerase II α.
Kim JS; Kim SY; Lee M; Kim SH; Kim SM; Kim EJ
Cancer Biol Ther; 2015; 16(4):558-66. PubMed ID: 25719218
[TBL] [Abstract][Full Text] [Related]
50. Epigenetic regulation of the KAI1 metastasis suppressor gene in human prostate cancer cell lines.
Sekita N; Suzuki H; Ichikawa T; Kito H; Akakura K; Igarashi T; Nakayama T; Watanabe M; Shiraishi T; Toyota M; Yoshie O; Ito H
Jpn J Cancer Res; 2001 Sep; 92(9):947-51. PubMed ID: 11572762
[TBL] [Abstract][Full Text] [Related]
51. Metastatic suppressor genes inactivated by aberrant methylation in gastric cancer.
Wang JF; Dai DQ
World J Gastroenterol; 2007 Nov; 13(43):5692-8. PubMed ID: 17963294
[TBL] [Abstract][Full Text] [Related]
52. Aberrant GRK6 promoter methylation is associated with poor prognosis in hypopharyngeal squamous cell carcinoma.
Qiu X; Chen J; Zhang Z; You Y; Wang Z
Oncol Rep; 2016 Feb; 35(2):1027-33. PubMed ID: 26718636
[TBL] [Abstract][Full Text] [Related]
53. Reactivation of Syk gene by AZA suppresses metastasis but not proliferation of breast cancer cells.
Xia TS; Shi JP; Ding Q; Liu XA; Zhao Y; Liu YX; Xia JG; Wang S; Ding YB
Med Oncol; 2012 Jun; 29(2):448-53. PubMed ID: 21347717
[TBL] [Abstract][Full Text] [Related]
54. The frequency of CpG and non-CpG methylation of Notch3 gene promoter determines its expression levels in breast cancer cells.
Xiao W; Liu X; Niu X; Li C; Guo Y; Tan J; Xiong W; Fan L; Li Y
Exp Cell Res; 2020 Jan; 386(2):111743. PubMed ID: 31770532
[TBL] [Abstract][Full Text] [Related]
55. Genomic screening for genes upregulated by demethylation revealed novel targets of epigenetic silencing in breast cancer.
Fujikane T; Nishikawa N; Toyota M; Suzuki H; Nojima M; Maruyama R; Ashida M; Ohe-Toyota M; Kai M; Nishidate T; Sasaki Y; Ohmura T; Hirata K; Tokino T
Breast Cancer Res Treat; 2010 Aug; 122(3):699-710. PubMed ID: 19859801
[TBL] [Abstract][Full Text] [Related]
56. Molecular Subtype-Specific Expression of MicroRNA-29c in Breast Cancer Is Associated with CpG Dinucleotide Methylation of the Promoter.
Poli E; Zhang J; Nwachukwu C; Zheng Y; Adedokun B; Olopade OI; Han YJ
PLoS One; 2015; 10(11):e0142224. PubMed ID: 26539832
[TBL] [Abstract][Full Text] [Related]
57. The role of PAQR3 gene promoter hypermethylation in breast cancer and prognosis.
Chen J; Wang F; Xu J; He Z; Lu Y; Wang Z
Oncol Rep; 2016 Sep; 36(3):1612-8. PubMed ID: 27461225
[TBL] [Abstract][Full Text] [Related]
58. Promoter methylation assay of SASH1 gene in breast cancer.
Sheyu L; Hui L; Junyu Z; Jiawei X; Honglian W; Qing S; Hengwei Z; Xuhui G; Qinghe X; Lin H
J BUON; 2013; 18(4):891-8. PubMed ID: 24344014
[TBL] [Abstract][Full Text] [Related]
59. Methylation of specific CpG sites in the P2 promoter of parathyroid hormone-related protein determines the invasive potential of breast cancer cell lines.
Tost J; Hamzaoui H; Busato F; Neyret A; Mourah S; Dupont JM; Bouizar Z
Epigenetics; 2011 Aug; 6(8):1035-46. PubMed ID: 21775817
[TBL] [Abstract][Full Text] [Related]
60. Methylation-dependent silencing of the reduced folate carrier gene in inherently methotrexate-resistant human breast cancer cells.
Worm J; Kirkin AF; Dzhandzhugazyan KN; Guldberg P
J Biol Chem; 2001 Oct; 276(43):39990-40000. PubMed ID: 11509559
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
